New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new radioactive drug, 177Lu-IM-3050, in about 105 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. Participants receive the drug and are monitored for side e…
Phase: EARLY_PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC